参考文献/References:
［1］Vergote I, Trope C G, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer ［J］. The New England Journal of Medicine, 2010, 363(10): 943-953.
［2］Rauh-Hain J A, Rodriguez N, Growdon W B, et al. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer ［J］. Annals of surgical oncology, 2012, 19(3): 959-965.
［3］Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial ［J］. Lancet, 2015, 386(9990): 249-257.
［4］Tangjitgamol S, Manusirivithaya S, Laopaiboon M, et al. Interval debulking surgery for advanced epithelial ovarian cancer ［J］. The Cochrane database of systematic reviews, 2016, 112（1）： CD006014.
［5］Chi D S, Musa F, Dao F, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT) ［J］. Gynecol Oncol, 2012, 124(1): 10-14.
［6］Colombo P E, Mourregot A, Fabbro M, et al. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients ［J］. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2009, 35(2): 135-143.
［7］Mueller J J, Zhou Q C, Iasonos A, et al. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center ［J］. Gynecol Oncol, 2016, 140(3): 436-442.
［8］Bristow R E, Chi D S. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis ［J］. Gynecol Oncol, 2006, 103(3): 1070-1076.
［9］Deborah K，Armstrong, Steven C，et al. NCCN clinical practice guildelines in oncology: ovarian caner including fallopian tube cancer and primary peritoneal cancer.version 2.2017 ［J］. J Natl Compr Canc Netw, 2017, 15:2-10.
［10］Makar A P, Trope C G, Tummers P, et al. Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer ［J］. The oncologist, 2016, 21(6): 745-754.
［11］Vergote I, Du Bois A, Amant F, et al. Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree? ［J］. Gynecol Oncol, 2013, 128(1): 6-11.
［12］Rutten M J, Sonke G S, Westermann A M, et al. Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer ［J］. Obstetrics and Gynecology International, 2015, 2015:464123.
［13］Neil S，Horowitz, Austin Miller, et al. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182 ［J］. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, 33(8): 937-943.
［14］Nick A M, Coleman R L, Ramirez P T, et al. A framework for a personalized surgical approach to ovarian cancer ［J］. Nature reviews Clinical oncology, 2015, 12(4): 239-245.
［15］Fagotti A, Ferrandina G, Fanfani F, et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study ［J］. Annals of surgical oncology, 2006, 13(8): 1156-1161.
相似文献/References:
[1]李菁,沈立翡,朱岚,等.新辅助化疗联合间隔减瘤术在晚期卵巢癌中的临床应用研究[J].中国计划生育和妇产科,2015,(11):0.
LI Jing,SHEN Li-fei,ZHU Lan,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2015,(4):0.
[2]史颖,李晓娟*.两种术前新辅助化疗给药方式对ⅠB2～ⅡA2期宫颈癌患者手术相关临床指标水平、生存时间及毒副作用的影响[J].中国计划生育和妇产科,2018,(8):86.
SHI Ying,LI Xiao-juan*.Influence of two ways of drug delivery of preoperative neoadjuvant chemotherapy on the operation-related clinical index, survival time and adverse reaction of patients with cervical cancer for Ⅰ B2～Ⅱ A2 stage[J].Chinese Journal of Family Planning & Gynecotokology,2018,(4):86.
[3]杨辰敏,冯炜炜,蔡蕾*.放化疗和手术的不同组合在治疗ⅡB~ⅣA期
宫颈癌的研究进展[J].中国计划生育和妇产科,2019,(6):30.
[4]朵雪莲*,马梅艳,白盖措.盆腔淋巴结切除数目对不同治疗方案的宫颈癌患者无进展生存时间的影响[J].中国计划生育和妇产科,2019,(9):47.
DUO Xue-lian*,MA Mei-yan,BAI Gai-cuo.Effect of number of pelvic lymph node resection on progression-free survival of cervical cancer patients with different treatment regimens[J].Chinese Journal of Family Planning & Gynecotokology,2019,(4):47.